Forward Pharma A/S reported unaudited consolidated earnings results for the six months ended June 30, 2017. For the six months, the company reported operating income of $1,213,594,000 compared to loss of $29,295,000 a year ago. Income before taxes was $1,213,010,000 compared to loss of $32,000,000 a year ago. Net income was $941,236,000 or $1.91 per diluted share compared to loss of $32,000,000 or $0.07 per diluted share a year ago. Net cash flows provided by operating activities was $1,211,049,000 compared to net cash flows used in operating activities of $15,772,000 a year ago. Purchase of equipment was $3,000 compared to $29,000 a year ago. During the six-month period ended June 30, 2017, the Company recognized as revenue the $1.25 billion nonrecurring Non-refundable Fee that was received during February 2017. The increase in 2017 in cash flows provided by operating activities is due to the receipt of the Non-refundable Fee of $1.25 billion offset by the royalty paid to Aditech Pharma AG of $25 million and other operating costs.